Log in

1177 Sino Biopharmaceutical Limited HKEX · Hong Kong

Sino Biopharmaceutical (1177) news

Sino Biopharmaceutical Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1177, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Sino Biopharmaceutical news

We have not published a story on Sino Biopharmaceutical yet. When there is news, it will appear here.

Questions about Sino Biopharmaceutical

What is the ticker symbol of Sino Biopharmaceutical?

Sino Biopharmaceutical Limited trades under the ticker 1177 on HKEX.

Where is Sino Biopharmaceutical listed?

Sino Biopharmaceutical Limited is listed on HKEX. Our directory also records these other listings: GETTEX:SMZ1; LS:A0CBDJ; OTC:SBHMY; OTC:SBMFF; SET:SINOBIO19.

What is the SEC CIK of Sino Biopharmaceutical?

The SEC Central Index Key (CIK) for Sino Biopharmaceutical Limited is 1604982. Its filings are on SEC EDGAR.

Which country or territory is Sino Biopharmaceutical listed under?

Our directory records Sino Biopharmaceutical Limited under Hong Kong.

What does Sino Biopharmaceutical do?

Our directory classifies Sino Biopharmaceutical Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Sino Biopharmaceutical?

The ISIN recorded for Sino Biopharmaceutical Limited is KYG8167W1380.

Does aibio.space cover Sino Biopharmaceutical?

aibio.space lists Sino Biopharmaceutical Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Sino Biopharmaceutical incorporated?

SEC records list its state or country of incorporation as E9.

Where is Sino Biopharmaceutical headquartered?

SEC records list its business address as 60 WALL STREET, NEW YORK, NY, 10005.

When does Sino Biopharmaceutical's fiscal year end?

Sino Biopharmaceutical Limited's fiscal year ends on December 31, per SEC records.

Which companies are similar to Sino Biopharmaceutical?

Companies in our directory listed in the same country and business area as Sino Biopharmaceutical: Extrawell Pharmaceutical Holdings, Regent Pacific Group, Pak Fah Yeow International, China Regenerative Medicine International, Beijing Tong Ren Tang Chinese Medicine Co., Dawnrays Pharmaceutical Holdings.

Investor discussion: Sino Biopharmaceutical

Members talk about Sino Biopharmaceutical (1177). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Sino Biopharmaceutical, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE. Source

  3. Listings

    Share consolidation: CHANGE OF STOCK SHORT NAME IN ENGLISH AND COMPANY WEBSITE. Source

  4. Financings

    Share or debt issue: SHARE TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE. Source

  5. Mergers

    Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FULL ACQUISITION OF LANOVA MEDICINES. Source

  6. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - FULL ACQUISITION OF LANOVA MEDICINES. Source

  7. Financings

    Share or debt issue: GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; ADOPTION OF THE NEW ARTICLES; AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Sino Biopharmaceutical's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - TQ-A3334 "TLR7 AGONIST" AND TQA3605 "CORE PROTEIN ALLOSTERIC MODULATOR" GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CDE

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF TQB2102 "HER2 BIPARATOPIC ADC" PRESENTED AT 2026 ESMO

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL PARTICIPANTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC2731 INJECTION "TSLP MONOCLONAL ANTIBODY" FOR CHRONIC SINUSITIS WITH NASAL POLYPS

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS ON TQ-A3334 "TLR7 AGONIST" AND BEPIROVIRSEN "ASO" TO BE PRESENTED AT 2026 AASLD

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL SUBJECTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR"

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC BIOSIMILARS PARTNERSHIP WITH STADA

  7. HKEXnews

    NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS

  8. HKEXnews

    NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQH2722 INJECTION

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQB2102 INJECTION "HER2 BISPECIFIC ADC"

  11. HKEXnews

    CONNECTED TRANSACTION - ACQUISITION OF 5% EQUITY INTEREST IN CT TIANQING THROUGH THE ACQUISITION OF EQUITY INTERESTS IN THE TARGET COMPANY

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - TQH5528 "ORAL STAT6 DEGRADER" PRECLINICAL STUDY DATA PRESENTED AT ERS 2026

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL DATA FOR TQC3721 INHALED POWDER FORMULATION, A "PDE3/4 INHIBITOR", PRESENTED AT ERS 2026

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB6426 "GPC3 ADC" APPROVED BY FDA

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR TQB2102 WITH CIPLA

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL TRIAL OF KYLO-11 "LPA SIRNA" PRESENTED AT ESC 2026 AND PUBLISHED IN THE LANCET

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-364 "NECTIN-4 TME ADC" APPROVED BY NMPA AND FDA

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF6422 INJECTION "ACTRIIA/B MONOCLONAL ANTIBODY" APPROVED BY THE NMPA

  19. HKEXnews

    INTERIM DIVIDEND FOR 2026

  20. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1177 on TradingView.

SEC filings and registration

SEC name
Sino Biopharmaceutical Limited/ADR
CIK
1604982
US tickers
SBMFF (OTC)
State or country of incorporation
E9
Fiscal year ends
December 31
Business address
60 WALL STREET, NEW YORK, NY, 10005
Phone
212-250-1905

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Sino Biopharmaceutical Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 1177, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Sino Biopharmaceutical Limited
Ticker
1177
Listing
HKEX
Country or territory
Hong Kong
Business scope
Pharmaceuticals: Major
ISIN
KYG8167W1380
Other listed symbols
GETTEX:SMZ1; LS:A0CBDJ; OTC:SBHMY; OTC:SBMFF; SET:SINOBIO19
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.